Mangiferin: a novel hepatoprotective for liver cirrhosis via modulation of histological, cellular, biochemical, inflammatory markers and oxidative stress Authors: Khaled Abdul-Aziz Ahmed, Suhayla Hamad Shareef, Haween Toufiq Nanakaly, Mohammed A. Ali, Derin Nabaz Fisal, Peshawa Yunis Aziz, Nabaz Fisal Shakir Agha, Mahmood Ameen Abdulla, Ahmed A. Salman Published: 2025 ABSTRACT Background and aimLiver cirrhosis is a global syndrome that develops from activation and proliferation of hepatic stellate cells, and following extracellular matrix accumulation. The current study evaluates the acute toxicity and prophylactic effects of mangiferin in thioacetamide (TAA)-induced liver damage in rats and its causal mechanisms.Experimental procedureThirty Sprague–Dawley rats were separate into five groups and treated for two months as follows: group (A) normal ingested orally daily 10% Tween 20 + distilled water (i.p.) (three times weekly); group (B) TAA control rats treated by mouth daily 10% Tween 20 + 200 mg/kg TAA i.p. (three times weekly); group (C) reference group received daily oral dose of 50 mg/kg silymarin + 200 mg/kg TAA i.p. (three times weekly); groups (D) rats received oral daily 30 mg/kg mangiferin + 200 mg/kg TAA i.p. (three times weekly); group (E) received oral daily 60 mg/kg mangiferin + 200 mg/kg TAA i.p. (three times weekly) for two months.ResultsThe non-toxic effects of mangiferin were evidenced by the lack of any toxicity incidence in rats ingested with up to 500 mg/kg. Gross morphological examination showed a regular liver architecture in mangiferin fed collections compared to hepatotoxic cluster. Histology of rat’s liver fed with mangiferin showed an important decrease in the liver index with hepatic cells propagation, mild cellular injury. Macroscopy of hepatotoxic liver exhibited irregular, rough surface with micro and macro nodules, and histopathology-stained Hematoxylin and Eosin (H&E), and Masson’s Trichome exhibited inflammation infiltration of lymphocytes, focal necrosis, fibrosis, and bile duct propagation. Immunohistochemistry examination of proliferation cellular nucleus antigen (PCNA), TAA inoculation stimulated cellular proliferation and apoptotic actions in damaged liver tissues, designated by increased PCNA. The TAA intraperitoneal inoculation caused significant hepatic dysfunction (lowered total protein, albumin levels, hepatotoxicity, and necrotic cell propagation). The TAA injection aggravated important hepatic intoxication inveterate by histopathological symptoms; change of tissue architecture, cellular propagation, and endothelial harm, enlarged hepatic nucleus, cytoplasmic vacuolation, collagen deposition, and raised necrotic tissues. The oxidative stress and inflammation process was markedly commenced subsequent TAA conveyance to rats proved by down-regulation of SOD, CAT, and IL-10, while, up-regulating the MDA and TNF-α and IL-6 cytokines.ConclusionNo toxicological signs were observed in rats administered 500 mg/kg of Mangiferin. Mangiferin supplementation showed significant resistance against TAA-mediated hepatotoxicity, reversed those cellular alterations, and restored liver functions. These results demonstrate significant ameliorative effects of mangiferin in TAA hepatotoxic rats, which could be attributed to its anti-apoptotic, antioxidant, and anti-inflammatory potentials, making it a possible viable hepatoprotective agent for inflammatory-related hepatitis. Introduction Liver diseases, comprising chiefly cirrhosis, viral hepatitis, and liver cancer, are responsible for more than two million annual deaths across the world. As the eleventh-leading cause of demise, liver disease explanations for 4% of all deaths (1 of every 25 deaths); approximately two-thirds of all liver-associated mortality occurrence is found in males [1]. Moreover, World Health Organization data from 2018 declared an increased age-standardized rate of liver cirrhosis with values of 15+ for every 100,000 individuals [2]. Liver cirrhosis considered result of prolonged hepatic damage due to harmful agents such as alcohol, fatty liver, and viral hepatitis [3]. The liver plays a sole role in the synthesis, metabolism, and excretory processes of substances from the portal circulation and, therefore, is sensitive to many toxic agents, drugs, and oxidative stress. Lipid peroxidation and oxidative stress are two major processes by which hepatotoxic chemicals can incite liver cirrhosis [4]. Chronic liver disease found alongside fibrosis, liver injury, and liver dysfunction increases non-functional plasm enzymes, including aspartate aminotransferase (AST), alkaline phosphatase (ALP), and Alanine aminotransferase (ALT) [5]. Proliferation cellular nucleus antigen (PCNA) is a nuclear protein that is considered a good indicator of cell proliferation. PCNA is considered a strong biomarker for the prognosis and survival rate in most solid cancer types, hepatocellular carcinoma. PCNA is an accurate reflector for the rates of necrotized cellular proliferation and transcriptional process (DNA formation) because of its aggregation in the late G1 and early S stages of mitosis. Early detection of PCNA intensity in hepatic biopsy of liver cirrhotic patients revealed increased expression of these proteins, indicating uncontrolled cellular proliferation [6]. Non-alcoholic fatty liver disease (NAFLD) is a prevalent clinical manifestation of metabolic syndrome, primarily distinguished by the accumulation of excessive fat in the liver, defined as more than 5% fat content. Importantly, NAFLD occurs independently of autoimmune factors, drug-induced effects, viral hepatitis, or a history of excessive alcohol consumption [9]. Cirrhosis is a late-stage organ failure of the liver that often requires a liver transplant, and liver cancer typically develops decades after cirrhosis or chronic hepatitis B infection. Both of these conditions are common causes of liver disease-related deaths in patients [10]. Natural products are significant resources for the enterprise and progress of new drugs to the goal of the hepatobiliary system [7, 8]. Among them, mangiferin as a natural phenolic xanthonoid is a novel bioactive compound derived from mango fruits and their by-products [9]. Based on recent investigations, Mangiferin has several therapeutic effects, including anti-apoptotic, antidiabetic, anti-inflammation, and antioxidant actions [10–12]. Herbs, medicinal plants, spices, vegetables, and crude drug substances are considered potential sources to combat various diseases including liver cirrhosis. In scientific literature, a large number of medicinal plants or their active ingredients with hepatoprotective potential have been reported [8, 13–16]. Mangiferin, a bioactive xanthonoid abundantly present in Mangiferia indica l., exerts multimodal therapeutic effects via NF-κB-mediated anti-inflammatory pathways and Nrf2-driven antioxidant mechanisms, as evidenced in preclinical models of atherosclerosis and diabetic vasculopathy. Mechanistically, it suppresses pro-inflammatory cytokine cascades while enhancing cellular redox defense [17]. Mangiferin exhibited antioxidant, anti-inflammatory, immunomodulatory, antibacterial, antidiabetic, neuroprotective activities and anti-obesity effects. Due to these effects, it is a promising adjuvant therapeutic to chronic disorders such as cardiovascular, renal, and pulmonary diseases; neurodegenerative disorders; obesity; diabetes; and metabolic syndrome [18]. Mangiferin reduces reactive oxygen species (ROS) levels in respiratory tissues and may enhance antioxidant activity [19]. Mangiferin, a natural phenolic compound in the form of xanthone glycoside, is the major bioactive compound found in various parts of mango, including the bark, leaves, fruit, and fruit peel [20]. Mangiferin significantly reduced NO, IL-1, IL-6, and TNF-ɑ by inhibiting activation of NF-κB in LPS-induced mouse microglia cells [21], and decreased IL-1, IL-6, and TNF-ɑ by inhibiting the nuclear translocation of the NF-Bp65 subunit in mononuclear macrophages, and protected mouse lung injury against sepsis [22]. Mangiferin alleviated the histopathology of inflammation and the levels of pro-inflammatory cytokines (TNF-ɑ, IL-1, and IL-6) via inhibiting NF-kB and NLRP3 inflammasome activation in lactating female mice [23]. Thioacetamide (TAA), a synthetic sulfur compound, is a potent hepatotoxic agent, causing liver injury and dysfunction through reactive oxygen species (ROS) generation and oxidative stress [24]. TAA passes through two steps of bio-activation, first to sulfine and then to sulfene. Sulfine causes nucleoli to grow, increases nuclear volume, alters cell permeability, and inhibits mitochondrial activity [25]. Simultaneously, sulfene triggers the release of nitric oxide synthase and nuclear factor kappa beta, which leads to protein denaturation, lipid peroxidation, and necrosis of the liver cells [26]. The liver parenchyma of rats exposed to a single dose of TAA (200 mg/kg) showed per-portal leukocyte cell infiltration, congested portal blood vessels, arteritis with thrombosis, and multifocal area of necrosis [24]. Thioacetamide (TAA), a sulfur-containing compound widely used as an experimental model for inducing liver fibrosis and cirrhosis, exerts its hepatotoxic effects through metabolic activation by cytochrome P450 enzymes in the liver. The resulting toxic metabolite, TAA-S-oxide, triggers a complex pathological cascade primarily through the generation of ROS and subsequent oxidative stress in hepatic tissue [27]. TAA oxidative insult triggers enhanced nuclear factor erythroid 2 related factor-2 (Nrf2) translocation to the nucleus, where it binds to antioxidant response elements to regulate key antioxidant enzymes, including glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT), that work synergistically to neutralise ROS [28]. Concurrently, TAA activates Kupffer cells to release pro-inflammatory cytokines including interleukin-1 beta (IL-1β) and tumour necrosis factor-alpha (TNF-α), initiating an inflammatory cascade [29]. Silymarin, a flavonolignan compound derived from the milk thistle herb (Silybum marianum), has demonstrated a critical role in the management and treatment of liver diseases, blood-related disorders, arthritis, ulcerative colitis, and cancer pathologies [30]. Silymarin is the extract of Silybum marianum, or milk thistle, and its major active compound is silybin, which has a remarkable biological effect. Numerous preclinical studies demonstrated that Silymarin has various biological activities such as antimicrobial, antiaging, anticancer, antidiabetic, neuroprotective, antioxidant, anti-inflammation activities and especially hepatoprotective effects [31]. Hepatoprotective effects of Silymarin have been extensively investigated in patients with various liver disorders such as viral hepatitis, alcoholic–associated liver diseases and drug-induced liver injuries [32]. Among its many hepatoprotective benefits are enhanced protein synthesis, cell regeneration, antioxidant activity, and anti-inflammatory and anti-fibrotic abilities [33]. Many studies by various co-researchers used silymarin as standard or reference drug for the hepatoprotection against TAA-induced liver injuries in laboratory animals [8, 15, 16, 34, 35]. To the best of our knowledge, there is no research on the hepatoprotective effects of mangiferin. Thus, this study was carried out to investigate the in vivo effect of mangiferin on TAA-induced liver cirrhosis in rats, which known to resemble liver injury seen in humans. Materials and methods Materials Mangiferin provided by Sigma-Aldrich Chemical Co. (USA) was prepared by dissolving in 10% Tween 20 and administered orally to the animals at dosages of 30 mg/kg and 60 mg/kg. [36] TAA was purchased from Sigma-Aldrich (Switzerland) was dissolved by sterile distilled water to obtain a homogeneous solution. Then, 200 mg/kg body weight was given through i.p injection to the rats thrice weekly for 8 weeks. Sterile distilled water was used to dissolve silymarin and administered orally to rats in doses of 50 mg/kg body weight [37]. Acute toxicity Thirty-six Sprague Dawley rats aged 7–8 weeks and weight around 190–200 g. Rats were divided into three wide-mesh wire cages (18 males and 18 females each) that were provided with rat’s diet and tape water throughout one-week acclimatization process. On the 8th day post-adaptation, altogether rats abstained (food but not water) overnight and were then nourished as follows in early morning: Group A normal control rats received 10% Tween 20 (5 mL/ kg); group B rats were oral gavage with 250 mg/kg of mangiferin; group C rats were oral gavage with 500 mg/kg of mangiferin. Rats were forbidden from food only for 3–4 h. post-feeding procedure. The regular check-up started instantly, and up to 3 days for any likely behavioral or physiological alterations. On day 14th whole animals were fast overnight (food but not water) and inoculated intramuscularly with an overdose of general anesthesia (3 mg/kg xylazine and 30 mg/kg ketamine) and euthanized on day 15th. Blood was collected from cardiac puncture. Blood was spine and separated serum specimens send to Central Medical Lab for analysis of biochemical parameters (liver and renal function tests), kidney and liver were removed rinsed with cold normal saline cut to small pieces 2 cm thickness and fixed in phosphate buffered formalin then send to Lab for tissue processing (automated tissue processing machine). Paraffin blocks sectioned 5 μm thickness stained with H & E stains and examined under microscope for any structural changes [16, 34]. Sprague dawley male rats Healthy adult Sprague Dawley male rats with age of 7–8 weeks and weight between (170–200 g) were obtained from the Animal House of Cihan University-Erbil. Individually caged rats with bottoms made of wide-mesh wire. Prior to the trial, animals were acclimated for a week in a typical laboratory setting while being fed a standard pellet diet and drinking tap water. Hepatoprotective protocol study Thirty adult male SD rats were randomly alienated into five groups with six rats each. For eight weeks, rats in the control group (Group 1) received an i.p. injection of sterile distilled water (5 ml/kg) three times per week with daily oral administration of 10% Tween 20 (5 ml/kg). Rats in the hepatotoxic group (Group 2) received 5 ml/kg of 10%Tween 20 orally and TAA 200 mg/kg i.p. thrice per week for eight weeks. Rats in the Group 3 (reference drug group) received TAA (200 mg/kg) three times per week by i.p. injection and silymarin (50 mg/kg) for 8 weeks. Finally, rats in Groups 4 and 5 (mangiferin-treated groups) received daily oral doses of 30 mg and 60 mg of mangiferin as well as three intraperitoneal injections per week of 200 mg of TAA for eight weeks. After 8 weeks, rats were starved for the night and sacrificed using ketamine (30 mg/kg, 100 mg/ml) and xylazine (3 mg/kg, 100 mg/ml) as anesthetics. Jugular vein was the site for blood samples collection from all rats. The blood was collected in gel-activated tubes, centrifuged, and examined for biochemical analysis such as ALP, ALT, AST, albumin, bilirubin, and protein in the Laboratory of Rizgary Hospital [38]. Histopathology Liver tissue sections were fixed in 10% phosphate-buffered formalin for 4–6 h, then trimmed into 2 cm thick sections, and further fixed overnight. The tissues underwent automated processing: 2 h in 70% alcohol, 2 h in 95% alcohol, 4 h in absolute alcohol, 4 h in xylene, and 4 h in liquid paraffin. The tissues were then embedded in paraffin using a tissue-processing machine (Leica, Germany), they were sliced at 5 μm thickness. Liver slices were incubated at 45 °C for 48 h and then divided into two groups. Group 1 was stained with hematoxylin and eosin (H&E) to assess histological abnormalities. Finally, the sections were mounted with DPX and analyzed under a microscope., while Group 2 was stained with Masson’s trichrome to evaluate liver fibrosis by quantifying collagen deposition using Adobe image analysis software [39]. In addition, PCNA immunostaining was accomplished as antecedently described [40]. The propagation of PCNA-stained liver slices was measured using a mitotic index, which was calculated by measuring the number of marked cells per 1000 liver cells [41]. Antioxidant activity and liver function tests All hepatic tissues were taken from the same location in the left lobe, far from the portal system. One gram of the tissue specimens was dissolved in 10 ml (10% w/v) of phosphate buffer saline (PBS) with pH 7.4, homogenized using a homogenizer, and then centrifuged at 4000 rpm for 10 min at 4 °C. [34] The supernatant was maintained in an -80 °C freezer and the different biochemical assays were carried out based on the manufacturer’s instructions. The levels of MDA were measured by using kit (Cat. No. LIP39-K01; from Eagle Biosciences, Boston, MA, USA), and CAT, and SOD were measured using kits from Cayman CAT assay kit (Cayman Ann Arbor, MI, USA) were estimated colorimetrically in liver homogenate according to the methods described by the manufacturer. Blood samples were used to estimate the liver function parameters including ALT (Cat. No. GOT111060), AST (Cat. No. GPT113100), ALP, bilirubin, albumin (Cat. No. ALB100250), and total protein (Cat. No. TP116250) were purchased from BioMed Diagnostics (Egy-Chem for lab technology Badr City, Egypt) were quantified spectrophotometrically in serum, using the previously mentioned commercial kits, following the manufacturer’s instructions. Serum inflammatory cytokines The ELISA particular Rat kits for TNF-α (E-EL-R2858), IL- 10 (E-EL-R00135), and IL- 6 (E-EL-R0012) cytokines were bought from Biotech Co. (Shanghai, China). The complete technique for the serum cytokine estimates can be found elsewhere [16]. Statistical analysis Statistical Package for the Social Sciences (SPSS) version 22 package (SPSS Inc, Chicago, IL, US) was used for analysis of data. Multiple comparisons were tested using one-way analysis of variance (ANOVA) with a post hoc analysis using Bonferroni test. Data are presented as mean ± standard error of the mean (S.E.M). The level of significance was set at p < 0.05. Results Acute toxicity Rats administered mangiferin 250 mg/kg and 500 mg/ kg were witnessed for 14 days. Rats were constantly lively and there were no substantial symbols of toxicity, atypical signs, change of behavior designs, body weight aberrations, or macroscopic detection observed during the whole investigate. There was no morbidity and mortality detected in both doses during the homework concerning the end of two weeks of experiment. A histological analysis of the liver, kidney (Fig. 1), and blood biochemical indicators presented no considerable changes observed between the different groups. Based on the results of the existing training, mangiferin was safe and not toxic to the investigational rats up to the high dose of 500 mg/kg through the training. Data for liver and kidney function test was not shown (but are available up on request). Fig. 1Histology slices kidney (upper row) and liver (bottom row) acute toxicity examination. Animals fed 10% Tween 20 negative collection (A, D); rats oral gavage 250 mg/kg of mangiferin (B, E); animal’s gavage 500 mg/kg of mangiferin (C, F). Kidney (upper row): Bowman’s capsule (yellow arrow), Glomerulus (blue arrow), renal convoluted tubule (green arrow); liver (bottom row): Central vein (blue arrow), and hepatic cords (black arrow). No substantial alterations noticed constructions livers and kidneys among treatment as well as control group (H & E stain, 20x) Histology slices kidney (upper row) and liver (bottom row) acute toxicity examination. Animals fed 10% Tween 20 negative collection (A, D); rats oral gavage 250 mg/kg of mangiferin (B, E); animal’s gavage 500 mg/kg of mangiferin (C, F). Kidney (upper row): Bowman’s capsule (yellow arrow), Glomerulus (blue arrow), renal convoluted tubule (green arrow); liver (bottom row): Central vein (blue arrow), and hepatic cords (black arrow). No substantial alterations noticed constructions livers and kidneys among treatment as well as control group (H & E stain, 20x) Liver weight and gross appearance Rats in the hepatotoxic group had considerably lower weights than those in the normal control, silymarin, or mangiferin groups. Silymarin or mangiferin-oral gavaged rats substantially exhibited increases in body weight and decreases in liver mass (Table 1). Table 1Effect of TAA on the body and liver weight of ratsAnimal GroupsBody weight (gm)Liver weight (gm)Liver Index (%)Normal control326 ± 2.23 c9.35 ± 0.10 b2.86 ± 0.03 cTAA control187 ± 2.04a12.47 ± 0.02 a6.64 ± 0.07 aTAA + Silymarin (50 mg/kg)295 ± 2.47 b9.71 ± 0.02 b3.28 ± 0.03 bTAA + Mangiferin (30 mg/kg)255 ± 3.40 b9.82 ± 0.02 b3.85 ± 0.05 bTAA + Mangiferin (60 mg/kg)241 ± 1.69 b9.68 ± 0.01 b4.01 ± 0.03 bThe values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a and b) within the same column are significantly different between groups as determined by Bonferroni’s post hoc test at a p < 0.05 significant level Table 1Effect of TAA on the body and liver weight of ratsAnimal GroupsBody weight (gm)Liver weight (gm)Liver Index (%)Normal control326 ± 2.23 c9.35 ± 0.10 b2.86 ± 0.03 cTAA control187 ± 2.04a12.47 ± 0.02 a6.64 ± 0.07 aTAA + Silymarin (50 mg/kg)295 ± 2.47 b9.71 ± 0.02 b3.28 ± 0.03 bTAA + Mangiferin (30 mg/kg)255 ± 3.40 b9.82 ± 0.02 b3.85 ± 0.05 bTAA + Mangiferin (60 mg/kg)241 ± 1.69 b9.68 ± 0.01 b4.01 ± 0.03 bThe values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a and b) within the same column are significantly different between groups as determined by Bonferroni’s post hoc test at a p < 0.05 significant level Effect of TAA on the body and liver weight of rats The values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a and b) within the same column are significantly different between groups as determined by Bonferroni’s post hoc test at a p < 0.05 significant level The surfaces of the livers in normal control rats were uniform and smooth. The liver was unevenly shaped and contained homogeneous micro nodules in the hepatotoxic group (Fig. 2). Treatment with either silymarin or mangiferin significantly improved the liver’s ability to recover from TAA damage to its structure and protected the liver from further deterioration. Fig. 2Influence of a mangiferin on the morphology of damaged liver brought on by TAA. There have been noticed differences in the macroscopic appearance of the liver. Silymarin and mangiferin-oral gavaged rats displayed a fairly smooth surface comparable to the normal group. Groups: (a) normal control, (b) thioacetamide control, (c) TAA + silymarin, (d) TAA + low dose mangiferin (30 mg/kg), and (e) TAA + high dose mangiferin (60 mg/kg) Influence of a mangiferin on the morphology of damaged liver brought on by TAA. There have been noticed differences in the macroscopic appearance of the liver. Silymarin and mangiferin-oral gavaged rats displayed a fairly smooth surface comparable to the normal group. Groups: (a) normal control, (b) thioacetamide control, (c) TAA + silymarin, (d) TAA + low dose mangiferin (30 mg/kg), and (e) TAA + high dose mangiferin (60 mg/kg) Effects of mangiferin on endogenous antioxidant enzymes activities SOD and CAT enzymatic activities in the liver homogenate were significantly decreased in the TAA-control group (hepatotoxic) when compared with the healthy control group. Rats oral gavaged with silymarin or mangiferin showed significantly higher enzymatic activities of SOD and CAT in comparison to the hepatotoxic group (Table 2). Levels of MDA, as an oxidative stress marker, were significantly increased in TAA-treated rats compared with normal control rats. Administration of silymarin or mangiferin expressively lowered MDA levels compared to the hepatotoxic group, bringing the level back to that of the normal controls (Table 2). Table 2Influence of mangiferin and Silymarin on the SOD, CAT and MDA contents of liver homogenate in the rats with cirrhosisAnimal GroupsSOD U/mg proteinCAT U/mg proteinMDA U/mg proteinHealthy control18.13 ± 0.64c38.05 ± 0.33c1.18 ± 0.01 bTAA control8.20 ± 0.05a18.48 ± 0.15a4.81 ± 0.08 aTAA + Silymarin (50 mg/kg)15.02 ± 0.20b37.59 ± 0.23c1.69 ± 0.04bTAA + Mangiferin (30 mg/kg)12.26 ± 0.32b25.94 ± 0.35b2.38 ± 0.09cTAA + Mangiferin (60 mg/kg)14.2 ± 0.27b37.26 ± 0.28c1.50 ± 0.03 bThe values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a, b, and c) within the same column are significantly different between groups as determined by ANOVA with p value of less than 0.05 Table 2Influence of mangiferin and Silymarin on the SOD, CAT and MDA contents of liver homogenate in the rats with cirrhosisAnimal GroupsSOD U/mg proteinCAT U/mg proteinMDA U/mg proteinHealthy control18.13 ± 0.64c38.05 ± 0.33c1.18 ± 0.01 bTAA control8.20 ± 0.05a18.48 ± 0.15a4.81 ± 0.08 aTAA + Silymarin (50 mg/kg)15.02 ± 0.20b37.59 ± 0.23c1.69 ± 0.04bTAA + Mangiferin (30 mg/kg)12.26 ± 0.32b25.94 ± 0.35b2.38 ± 0.09cTAA + Mangiferin (60 mg/kg)14.2 ± 0.27b37.26 ± 0.28c1.50 ± 0.03 bThe values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a, b, and c) within the same column are significantly different between groups as determined by ANOVA with p value of less than 0.05 Influence of mangiferin and Silymarin on the SOD, CAT and MDA contents of liver homogenate in the rats with cirrhosis The values were presented as mean ± S.E.M (n = 6). The values of different superscripts (a, b, and c) within the same column are significantly different between groups as determined by ANOVA with p value of less than 0.05 Effects of mangiferin on biochemical parameters Hepatic parenchymal tissues have been damaged by TAA, and the severity of this damage has been determined by measuring the serum bilirubin levels, ALP, ALT, and AST. These hepatic enzymes were elevated in the TAA-control group as a result of their leakage due to tissue damage. Rats given silymarin or mangiferin have drastically reduced these enzyme and bilirubin levels. (Table 3). Levels of protein and albumin were significantly lower in hepatotoxic rats than silymarin or mangiferin-treated groups, indicating acute hepatocellular damage. Silymarin or mangiferin-treated groups restored the albumin and protein levels closer to their normal levels. As a result, silymarin or mangiferin restored the liver’s normal physiology and reduced the harmful effects of TAA (Table 3). Table 3The effects of mangiferin and silymarin on the liver function tests in TAA-induced toxicity in the rat’s liversGroupsALPIU/LALTIU/LASTIU/LT. Bilirubing/LProteing/LAlbuming/LNormal Control73.67 ± 1.11*35.33 ± 0.71*56.33 ± 1.25*1.175 ± 0.02 *65.17 ± 0.94*23.33 ± 0.76*TAA control229.0 ± 2.12#156.4 ± 1.67#219.3 ± 1.89#4.59 ± 0.03#46.27 ± 0.9#7.95 ± 0.25#TAA + Silymarin (50 mg/kg)77.61 ± 1.16#36.64 ± 1.0#62.62 ± 1.37*#0.82 ± 0.05*#65.24 ± 1.03#23.74 ± 0.93#TAA + Mangiferin (30 mg/kg)85.37 ± 1.11*#82.11 ± 0.86*#86.38 ± 1.06*#2.42 ± 0.02*#61.76 ± 0.44#18.29 ± 0.69*#TAA + Mangiferin (60 mg/kg)74.71 ± 1.15#37.40 ± 1.06#63.15 ± 1.15*#1.24 ± 0.01#66.89 ± 0.61#24.50 ± 0.52#Values are mean ± SEM (n = 6 rats/group). Values indicated by different superscripts are suggestively significant difference according to bonferroni’s post-hoc test. *p < 0.05 against healthy group and # p < 0.05 against TAA group. ALT; alanine aminotransferase, AST; aspartate aminotransferase, ALP; alkaline phosphatase, TAA; thioacetamide Table 3The effects of mangiferin and silymarin on the liver function tests in TAA-induced toxicity in the rat’s liversGroupsALPIU/LALTIU/LASTIU/LT. Bilirubing/LProteing/LAlbuming/LNormal Control73.67 ± 1.11*35.33 ± 0.71*56.33 ± 1.25*1.175 ± 0.02 *65.17 ± 0.94*23.33 ± 0.76*TAA control229.0 ± 2.12#156.4 ± 1.67#219.3 ± 1.89#4.59 ± 0.03#46.27 ± 0.9#7.95 ± 0.25#TAA + Silymarin (50 mg/kg)77.61 ± 1.16#36.64 ± 1.0#62.62 ± 1.37*#0.82 ± 0.05*#65.24 ± 1.03#23.74 ± 0.93#TAA + Mangiferin (30 mg/kg)85.37 ± 1.11*#82.11 ± 0.86*#86.38 ± 1.06*#2.42 ± 0.02*#61.76 ± 0.44#18.29 ± 0.69*#TAA + Mangiferin (60 mg/kg)74.71 ± 1.15#37.40 ± 1.06#63.15 ± 1.15*#1.24 ± 0.01#66.89 ± 0.61#24.50 ± 0.52#Values are mean ± SEM (n = 6 rats/group). Values indicated by different superscripts are suggestively significant difference according to bonferroni’s post-hoc test. *p < 0.05 against healthy group and # p < 0.05 against TAA group. ALT; alanine aminotransferase, AST; aspartate aminotransferase, ALP; alkaline phosphatase, TAA; thioacetamide The effects of mangiferin and silymarin on the liver function tests in TAA-induced toxicity in the rat’s livers Values are mean ± SEM (n = 6 rats/group). Values indicated by different superscripts are suggestively significant difference according to bonferroni’s post-hoc test. *p < 0.05 against healthy group and # p < 0.05 against TAA group. ALT; alanine aminotransferase, AST; aspartate aminotransferase, ALP; alkaline phosphatase, TAA; thioacetamide Histopathological examination In the normal healthy rats’ group, livers did not show any pathological abnormalities. The central vein, hepatic cords, sinusoidal space, nucleus, and entire cytoplasm of the liver cells were all present as revealed in (Fig. 3a (on the left)). Hepatotoxic group showed structural cell damage, inflammation, vacuolation, fatty changes, sinusoidal dilatation, focal centrilobular necrosis, and hepatocytes proliferation in the corresponding liver sections (Fig. 3b (on the left)). Collagen bridges generated by fibrous septa associated with bile duct proliferation, mononuclear cell infiltration, and change hepatic construction, which deformed the liver parenchyma architecture, distinguished the small and large regenerating nodules of liver necrosis. The liver separated into pseudo-lobules by strong fibrous septa that encircled the nodules. With the portal triad, enlarged portal tracts, and collagen deposition, there were indications of cytoplasmic vacuolization, hepatocyte necrosis, and infiltration of inflammatory cells. Silymarin group presented slight collagen fibers deposition with fewer dense fibrous septa deposition suggestion minimal fibrosis (Fig. 3c (on the left)). Mangiferin-treated rats group showed significantly less pathological changes as likened to hepatotoxic rats (Fig. 3d (on the left)). TAA-induced edema, hepatic necrosis, lymphocyte infiltration, and the growth of fibrous connective tissue all inhibited by administration of mangiferin (Fig. 3e (on the left)). Fig. 3Hepatic tissue sections were examined histopathological using hematoxylin and eosin stain (left) and Masson’s trichrome (right). The liver histopathology sections from the following groups shown: (a) normal group; no abnormalities in the hepatic sinusoids or portal vein, (b) TAA group (Hepatotoxic group showed significant liver damage, including cellular damage, inflammation (black arrow), necrosis, collagen deposition and fibrosis (blue arrow), dilatation of hepatic sinusoids (asterisk) and fatty changes, (c) TAA + silymarin group, (d) TAA + mangiferin 30 mg/kg (hepatic cords (green arrow)), and (e) TAA + mangiferin 60 mg/kg (silymarin and mangiferin groups showed minimal fibrosis with slight collagen deposition (arrow)). (Stained liver sections were shown at 20x magnification) Hepatic tissue sections were examined histopathological using hematoxylin and eosin stain (left) and Masson’s trichrome (right). The liver histopathology sections from the following groups shown: (a) normal group; no abnormalities in the hepatic sinusoids or portal vein, (b) TAA group (Hepatotoxic group showed significant liver damage, including cellular damage, inflammation (black arrow), necrosis, collagen deposition and fibrosis (blue arrow), dilatation of hepatic sinusoids (asterisk) and fatty changes, (c) TAA + silymarin group, (d) TAA + mangiferin 30 mg/kg (hepatic cords (green arrow)), and (e) TAA + mangiferin 60 mg/kg (silymarin and mangiferin groups showed minimal fibrosis with slight collagen deposition (arrow)). (Stained liver sections were shown at 20x magnification) Masson trichrome stain (MT stains) determined the degree of fibrosis in liver slices. Liver sections of normal cluster revealed normal and integral and no symbol of collagen deposition or hepatic tissue necrosis (Fig. 3a (on the right)). In hepatotoxic collection, liver slices displayed increase of collagen fibers deposition with dense fibrous septa between lobules and around the congested central vein and bile duct proliferation in hepatic trade (Fig. 3b (on the right)). Liver tissues from Silymarin group presented slight collagen fibers deposition with fewer dense fibrous septa deposition suggestion minimal fibrosis (Fig. 3c (on the right)). Similar liver tissue of rat’s oral gavage with 30 mg/kg mangiferin showed moderate collagen fiber deposition between lobes in liver parenchyma (Fig. 3d (on the right)), However, liver tissue of rat’s gavage orally 60 mg/kg mangiferin exhibited mild collagen deposition with mild congestion around the central vein (Fig. 3e (on the right)). These microscopic evaluation of liver slices confirmed that manigiferin excerpt knowledgeably resisted hepatocytes fibrosis analogous to that of silymarin. Immunohistochemically stain liver of sections TAA-induced liver damage and consequence of mangiferin extract examined by immunohistochemical stains of PCNA expression in the liver parenchyma using specific antibody. Normal control collection showed down-regulation of PCNA stains, signified no cell renewal happening (Fig. 4a). Quite the reverse, the TAA treated hepatotoxic control group had remarkable PCNA expression suggesting up-regulation of these proteins with higher level of hepatocyte fibrosis (Fig. 4b). This group elevated the mitotic figure index significantly signifying propagation to renewal widespread hepatic damages produced by TAA (Table 4). Fig. 4Effect of mangiferin extract on PCNA staining of liver. (a) Normal control group, no PCNA staining, (b) TAA group, PCNA expression hepatocyte nuclei (up-regulation) (yellow arrows) and collagen deposition (yellow asterisk), (c) TAA + 50 mg/kg silymarin group, mild PCNA expression of hepatocyte nuclei (down-regulation) (yellow arrows), (d) TAA + 30 mg/kg mangiferin group, mild to moderate appearance PCNA positive hepatocyte nuclei (down-regulation) (yellow arrows), (e) TAA + 60 mg/kg mangiferin group, mild PCNA positive hepatocyte nuclei (down-regulation) (yellow arrows) and diffuse fatty change of hepatic cells (green asterisk). (PCNA Stained liver sections 20x magnification) Effect of mangiferin extract on PCNA staining of liver. (a) Normal control group, no PCNA staining, (b) TAA group, PCNA expression hepatocyte nuclei (up-regulation) (yellow arrows) and collagen deposition (yellow asterisk), (c) TAA + 50 mg/kg silymarin group, mild PCNA expression of hepatocyte nuclei (down-regulation) (yellow arrows), (d) TAA + 30 mg/kg mangiferin group, mild to moderate appearance PCNA positive hepatocyte nuclei (down-regulation) (yellow arrows), (e) TAA + 60 mg/kg mangiferin group, mild PCNA positive hepatocyte nuclei (down-regulation) (yellow arrows) and diffuse fatty change of hepatic cells (green asterisk). (PCNA Stained liver sections 20x magnification) Table 4Effect of mangiferin extract on PCNA stain and mitotic indexGroupsPCNA stainsMitotic IndexNormal control0.000.00TAA + 10% Tween 2025.4 ± 1.8#65.3 ± 5.2#TAA + Silymarin 50 mg/kg1.7 ± 0.33*12.15 ± 1.3*TAA + 30 mg/kg8.6 ± 0.17*30.24 ± 3.5*TAA + 60 mg/kg5.4 ± 0.6*14.5 ± 2.6*Data expressed as Mean ± SEM. (n = 6 rats/group). *p < 0.05 compared with TAA control cluster, #p < 0.05 compared with normal control group Table 4Effect of mangiferin extract on PCNA stain and mitotic indexGroupsPCNA stainsMitotic IndexNormal control0.000.00TAA + 10% Tween 2025.4 ± 1.8#65.3 ± 5.2#TAA + Silymarin 50 mg/kg1.7 ± 0.33*12.15 ± 1.3*TAA + 30 mg/kg8.6 ± 0.17*30.24 ± 3.5*TAA + 60 mg/kg5.4 ± 0.6*14.5 ± 2.6*Data expressed as Mean ± SEM. (n = 6 rats/group). *p < 0.05 compared with TAA control cluster, #p < 0.05 compared with normal control group Effect of mangiferin extract on PCNA stain and mitotic index Data expressed as Mean ± SEM. (n = 6 rats/group). *p < 0.05 compared with TAA control cluster, #p < 0.05 compared with normal control group Rat oral gavage 60 mg/kg mangiferin extract had condensed hepatic cells renewal in comparing to the TAA treated hepatotoxic control group, as indicated by PCNA appearance and a significant reduction of the mitotic index (Fig. 4e; Table 4). Whereas 30 mg/kg mangiferin extract showed moderate expressions of PCNA within the hepatocytes with significant decrease in mitotic figure index but not comparable to silymarin treated group (Fig. 4d; Table 4). These results suggest mangiferin extract had an estimable hepatoprotective effect by inhibiting fibrosis of hepatocytes and ameliorating propagation (PCNA stain 20x magnification). Effect of mangiferin on inflammatory cytokines The intraperitoneal inoculation of TAA incited inflammation in the investigational animals. Normal control group displayed condensed serum incendiary pointers, counting reduced pro-inflammatory cytokines (TNF-α, IL-6) and improved IL- 10 cytokines (anti-inflammatory cytokine). The TAA control cluster revealed Spartan inflammatory state, signified by raised TNF-α and IL- 6) and lowermost IL- 10 likened to rat’s groups in C, D, and E groups. Rats’ oral gavage with silymarin (50 mg/kg) or mangiferin (30 and 60 mg/kg) presented noteworthy resistance to TAA-convinced inflammation, signified by decreased TNF-α, IL- 6 and rise IL-10. The current signals demonstration substantial hepatoprotective promises of mangiferin against TAA-induced cytotoxic effects, proven by its improving effects on the inflammatory conditions that were significantly far away from values of TAA-control group (Fig. 5). Fig. 5Influence of mangiferin on the serum provocative cytokines in TAA-convinced hepatotoxicity in rats. A, normal control group fed only 10% Tween 20; group B, rats received i.p injection of TAA + 10% Tween 20; group C, rats received i.p inoculation of TAA + Silymarin 50 mg/kg orally; group D, rats received i.p injection of TAA + 30 mg/kg mangiferin oral; group E, rats had i.p injection of TAA + 60 mg/ kg of mangiferin gavage orally. Intraperitoneal injection of TAA incited an important inflammatory state, as seen in group B rats. In contrast, rats fed with mangiferin or silymarin prevented TAA-induced incendiary change that eventually caused in inferior TAA- convinced hepatic damage likened to TAA-control group Influence of mangiferin on the serum provocative cytokines in TAA-convinced hepatotoxicity in rats. A, normal control group fed only 10% Tween 20; group B, rats received i.p injection of TAA + 10% Tween 20; group C, rats received i.p inoculation of TAA + Silymarin 50 mg/kg orally; group D, rats received i.p injection of TAA + 30 mg/kg mangiferin oral; group E, rats had i.p injection of TAA + 60 mg/ kg of mangiferin gavage orally. Intraperitoneal injection of TAA incited an important inflammatory state, as seen in group B rats. In contrast, rats fed with mangiferin or silymarin prevented TAA-induced incendiary change that eventually caused in inferior TAA- convinced hepatic damage likened to TAA-control group Discussion The Acute toxicity examination did not show any signs of toxicity, morbidity or mortality throughout the two weeks of experiment. There were no structural changes of liver and kidney histology between collections of rats. In addition, there were no alteration in serum biochemical parameters (liver and kidney functions) among animal’s clusters. In addition, no variation in the body heaviness between assemblies. Similarly, in scientific literatures several studies utilizing medicinal plants or their active ingredient did not observe any toxic effect in histology of liver, kidney, and serum biochemistry strictures have been reported by abundant investigators [8, 16, 34, 35, 42]. In the present study, there was a significant reduction in body weight in the hepatotoxic group compared to normal control. In contrast, liver weight increased significantly in the TAA control group. Findings of the current study were in line with the previously reported investigation [8, 43]. In contrast, mangiferin therapy reduced liver weight to virtually normal levels. Similar results were previously reported [13, 14]. One possible explanation for this effect is a reduction in inflammation [16, 41, 44]. Rats belonging to the hepatotoxic group displayed hepatomegaly. The higher liver weight/body weight ratio in the TAA control group was caused by fat buildup and liver deterioration. This finding agreed with a prior study that found an increased liver weight/body weight ratio in hepatotoxic rats [16, 45, 46]. In rats, TAA injection resulted in hepatic cirrhosis. Mangiferin treatment alleviated the damage significantly. These observations are in line with previous studies [8, 43, 47]. Our findings demonstrated that mangiferin can considerably accelerate recovery from liver injury and prevent the effect of TAA, as previously demonstrated elsewhere [24, 34, 43]. The decrease in hyperlipidemia may be the cause of the liver/body weight reduction observed with mangiferin treatment [14, 15, 48]. Our findings showed that blood levels of the liver biomarkers ALP, ALT, and AST significantly increased in response to TAA-induced hepatotoxicity. Taking mangiferin considerably decreased these readings. Several researchers have previously reported similar findings of serum liver biomarkers improving with various plant treatments. [8, 13, 49] According to previous investigations, TAA damages membranes and prevents RNA from moving from the nucleus to the cytoplasm. This causes an increase in the production of serum liver markers. [44, 50] It is recognized that following cell damage, the capacity for protein synthesis declines and that the levels of these proteins in the plasma will typically decrease as the degree of the damage increases [16, 51]. Similar findings were obtained in our study, mangiferin brought these protein levels back to normal, indicating a transition from the aberrant condition to the normal state [14, 34]. TAA was utilized in the current investigation, is a chemical that has been demonstrated to cause hepatotoxicity in research animal models [52, 53] Cirrhosis of the liver is distinguished by inappropriate rebuilding of the lobular architecture, the appearance of widespread fibrosis addition, and nodular lesions of the liver parenchyma. [43, 54, 55] Cirrhosis of the liver is a serious condition that is accompanied by several pathological conditions, such as increasing fibrosis, portal hypertension, and cancer. Fibrosis and cirrhosis progress because of free radical production, mitochondrial malfunction, and antioxidant depletion. [8, 56]. Lipid peroxidation is a complex and unfavorable process, used to describe the oxidative breakdown of lipids. Because of the increase in MDA in the liver, lipid peroxidation has been accelerated, resulting in tissue damage and a breakdown of the antioxidant defense mechanisms that would otherwise be able to prevent the overproduction of free radicals. [16, 57, 58] Thioacetamide increased MDA levels in the TAA control group in the current investigation, whereas mangiferin treatment significantly decreased MDA levels, indicating reduced lipid peroxidation. Thus, the higher MDA could be explained by the TAA control group’s reduced hepatic antioxidant enzyme activity. In the present study, PCNA was shown to be down-regulated in silymarin-fed or normal liver clusters, indicating the absence of cell renewal. In a hepatotoxic assembly, there was evidence of up-regulation of PCNA-appearing hepatic cells, which indicates broad dissemination and likely attempts to repair tissue damage. Then, rats fed with mangiferin significantly condensed cell proliferation records as explained by the decline in PCNA stain. TAA-induced liver injury in rats administered with plant extracts has previously been reported to have PCNA levels that were downregulated [40, 44, 59, 60]. In the current investigation, SOD and CAT activities were observed to be significantly higher in the hepatic homogenates of rats supplemented with mangiferin, whereas MDA levels were decreased in the rats given TAA. These findings are consistent with prior studies published by other academics. [34, 61, 62] TAA injection can result in a slow increase in liver pro-inflammatory cytokines (IL- 6 and TNF-α), which eventually trigger the NF-κB mechanism and additional hepatocyte damage. As significant controller and synthetic organ of provocative cytokines, the liver is self-same reactive to TAA- convinced inflammatory cytokine relief by macrophages. Additionally, TAA hepatic Kupffer cells (hepatic macrophages) produce extra pro-inflammatory cytokines and trigger hepatic inflammatory cascade that consequently improves additional ROS creation and oxidative stress-mediated liver damage. Similar with the above information, the current study presented raised IL-6 and TNF-α cytokines and condensed IL-10 in TAA-control collection. Daily nourished with silymarin or mangiferin displayed substantial resistance against TAA-induced oxidative hepatic injury presented by enhanced provocative condition and inferior inflammatory mediators likened to TAA-control cluster. Consistent with the results of the present works many studies using medicinal plant extracts or their active constituents in TAA-induced liver cirrhosis in rats showed decreased pro-inflammatory cytokines and increased anti-inflammatory cytokines have been reported by huge numbers of academic [16, 34]. Conclusions Our study reveals that mangiferin exhibits significant hepatoprotective effects against TAA-induced liver damage in rats, as demonstrated by improvements in macroscopic appearance, histological analysis, immunohistochemical markers, and biochemical liver parameters. Specifically, mangiferin treatment enhanced antioxidant defenses by increasing serum CAT and SOD levels while reducing hepatic MDA levels. Furthermore, mangiferin down-regulated PCNA expression, suggesting a potential mechanism for its protective effects. The hepatoprotective properties of mangiferin may be attributed to its antioxidant, anti-fibrotic, and anti-inflammatory activities, which collectively mitigate oxidative stress and inflammation. These findings suggest mangiferin’s potential therapeutic value in preventing or treating liver damage. Study limitations This study’s findings are subject to several limitations. The small sample size and resource constraints may have influenced the results. Additionally, the study’s scope was restricted due to limited access to laboratory equipment. Furthermore, the study was limited to two doses of mangiferin, and exploring a wider range of doses may provide more comprehensive insights. The study also employed a limited range of staining techniques, and other immunohistochemical stains, such as those for Ki-67, TUNEL, caspase-3, TGF-β, and NF-κB, may offer additional information on cellular proliferation, apoptosis, fibrosis, and inflammation. Incorporating these stains could provide a more detailed understanding of the underlying mechanisms and potential therapeutic applications of mangiferin.